JP7070933B2 - アセトアルデヒド毒性を低減するためのβ－エスシンを含有する経口組成物 - Google Patents

アセトアルデヒド毒性を低減するためのβ－エスシンを含有する経口組成物 Download PDF

Info

Publication number
JP7070933B2
JP7070933B2 JP2019528118A JP2019528118A JP7070933B2 JP 7070933 B2 JP7070933 B2 JP 7070933B2 JP 2019528118 A JP2019528118 A JP 2019528118A JP 2019528118 A JP2019528118 A JP 2019528118A JP 7070933 B2 JP7070933 B2 JP 7070933B2
Authority
JP
Japan
Prior art keywords
escin
composition
alcohol
concentration
chokeberry
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019528118A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535779A (ja
JP2019535779A5 (cg-RX-API-DMAC7.html
Inventor
コジアク，カタルツィナ
Original Assignee
エスシラブ エスペー．ゾー．オー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エスシラブ エスペー．ゾー．オー． filed Critical エスシラブ エスペー．ゾー．オー．
Publication of JP2019535779A publication Critical patent/JP2019535779A/ja
Publication of JP2019535779A5 publication Critical patent/JP2019535779A5/ja
Application granted granted Critical
Publication of JP7070933B2 publication Critical patent/JP7070933B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
JP2019528118A 2016-11-24 2017-11-24 アセトアルデヒド毒性を低減するためのβ－エスシンを含有する経口組成物 Active JP7070933B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1619846.7A GB201619846D0 (en) 2016-11-24 2016-11-24 Saponin composition
GB1619846.7 2016-11-24
PCT/IB2017/057395 WO2018096502A1 (en) 2016-11-24 2017-11-24 Oral compositions comprising beta-escin for reducing acetaldehyde toxicity

Publications (3)

Publication Number Publication Date
JP2019535779A JP2019535779A (ja) 2019-12-12
JP2019535779A5 JP2019535779A5 (cg-RX-API-DMAC7.html) 2021-01-07
JP7070933B2 true JP7070933B2 (ja) 2022-05-18

Family

ID=58073282

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019528118A Active JP7070933B2 (ja) 2016-11-24 2017-11-24 アセトアルデヒド毒性を低減するためのβ－エスシンを含有する経口組成物

Country Status (9)

Country Link
US (1) US10799550B2 (cg-RX-API-DMAC7.html)
EP (1) EP3544615B1 (cg-RX-API-DMAC7.html)
JP (1) JP7070933B2 (cg-RX-API-DMAC7.html)
KR (1) KR102569055B1 (cg-RX-API-DMAC7.html)
AU (1) AU2017365116B2 (cg-RX-API-DMAC7.html)
CA (1) CA3044504A1 (cg-RX-API-DMAC7.html)
GB (1) GB201619846D0 (cg-RX-API-DMAC7.html)
PL (2) PL430029A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018096502A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2992157T3 (es) * 2018-10-05 2024-12-09 Escilab Sp Z O O Composición oral que comprende b-escina y el uso de la misma
CN116159145B (zh) * 2023-01-31 2025-04-22 四川大学 含七叶皂苷和/或其盐化合物的转染复合物在促转染的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3533231B2 (ja) * 1993-08-20 2004-05-31 森下仁丹株式会社 アルコール吸収抑制剤
JP4777495B2 (ja) * 1999-04-01 2011-09-21 森下仁丹株式会社 アルコール障害予防剤およびそれを含有する食品
DK1976391T3 (da) * 2005-12-30 2011-01-10 Cadbury Holdings Ltd Tyggegummipræparat indeholdende aroniabær
KR101383276B1 (ko) * 2012-03-05 2014-04-08 염장열 아로니아 음료 농축액 및 그 제조방법
KR20140090453A (ko) * 2013-01-09 2014-07-17 (주) 제이비케이자연의학연구소 아로니아 추출물을 함유하는 숙취예방, 숙취해소 또는 간 보호용 조성물
PL405318A1 (pl) * 2013-09-11 2015-03-16 Cezary Bilski Preparat złożony wspomagający odchudzanie na bazie wyciągów roślinnych
KR20160100572A (ko) * 2015-02-16 2016-08-24 학교법인연세대학교 고미가 제거된 남가새 음료 및 이의 제조방법
EP3078381A1 (en) * 2015-04-10 2016-10-12 Warszawski Uniwersytet Medyczny Horse chestnut extract or escins for the treatment of alzheimer's disease

Also Published As

Publication number Publication date
US10799550B2 (en) 2020-10-13
AU2017365116B2 (en) 2023-06-22
JP2019535779A (ja) 2019-12-12
KR20190087437A (ko) 2019-07-24
US20190321432A1 (en) 2019-10-24
KR102569055B1 (ko) 2023-08-21
EP3544615B1 (en) 2022-05-18
PL3544615T3 (pl) 2022-09-19
EP3544615A1 (en) 2019-10-02
CA3044504A1 (en) 2018-05-31
WO2018096502A1 (en) 2018-05-31
AU2017365116A1 (en) 2019-05-23
PL430029A1 (pl) 2021-03-08
GB201619846D0 (en) 2017-01-11

Similar Documents

Publication Publication Date Title
Akinyemi et al. Effect of dietary supplementation of ginger and turmeric rhizomes on angiotensin-1 converting enzyme (ACE) and arginase activities in L-NAME induced hypertensive rats
Bondonno et al. Dietary flavonoids and nitrate: effects on nitric oxide and vascular function
Elnaga et al. Effect of stevia sweetener consumption as non-caloric sweetening on body weight gain and biochemical’s parameters in overweight female rats
TW542721B (en) Dietary supplements containing natural ingredients
Panza et al. Effects of mate tea consumption on muscle strength and oxidative stress markers after eccentric exercise
Sharma et al. Cinnamaldehyde, an active component of cinnamon provides protection against food colour induced oxidative stress and hepatotoxicity in albino Wistar rats
Johnson et al. Dopamine toxicity following long term exposure to low doses of 3-nitropropionic acid (3-NPA) in rats
JP7070933B2 (ja) アセトアルデヒド毒性を低減するためのβ－エスシンを含有する経口組成物
Yang et al. Tochu (Eucommia ulmoides) leaf extract prevents ammonia and vitamin C deficiency induced gastric mucosal injury
Babizhayev New concept in nutrition for the maintenance of the aging eye redox regulation and therapeutic treatment of cataract disease; synergism of natural antioxidant imidazole-containing amino acid-based compounds, chaperone, and glutathione boosting agents: a systemic perspective on aging and longevity emerged from studies in humans
US20160331798A1 (en) Natural product inhibitors of 3dg
EP4486354A1 (en) Bioactives and their uses
HK40015220A (en) Oral compositions comprising beta-escin and chokeberry juice for reducing acetaldehyde toxicity
HK40015220B (en) Oral compositions comprising beta-escin and chokeberry juice for reducing acetaldehyde toxicity
US20250090564A1 (en) Bioactives and their uses
US12364730B2 (en) Composition comprising oil palm phenolics for use in the treatment and prevention of colon diseases and for promoting and maintaining gut and general health
Mesas et al. Antioxidant and Chemopreventive Activity of Protein Hydrolysates from Raw and Germinated Flour of Legumes with Commercial Interest in Colorectal Cancer. Antioxidants 2022, 11, 2421
Thorley The effect of exercise and nutritional interventions on promoting adaptations to redox signalling
Harwanto et al. The hot water extract and active components nicotinamide and guanosine of the leather carp Cyprinus carpio nudis improve exercise performance in mice
Ferreira et al. Olive Oil and huntington’s disease
WO2025048651A1 (en) Bioactives and their uses
EP3357541B1 (en) Methylsulfonylmethane composition for reducing blood alcohol content
Stockley Is there a role for wine in cancer and the degenerative diseases of aging?
Prasad et al. To investigate the antioxidant property of GINGER-JUICE (ZINGIBER OFFICINALE ROSCOE) using established antioxidant parameters.
Davies Plenary Lectures and Oral Presentations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201120

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210907

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220405

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220425

R150 Certificate of patent or registration of utility model

Ref document number: 7070933

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R154 Certificate of patent or utility model (reissue)

Free format text: JAPANESE INTERMEDIATE CODE: R154

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250